Nuvation Bio Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. The interim financial statements are unaudited. Nuvation Bio is a clinical-stage oncology biopharmaceutical company and has no commercially approved products.
Financial results and liquidity
Amounts below are in millions of dollars, except per-share data. The company reported no product, collaboration, or other revenue; therefore, a revenue margin is not applicable.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Research and development expense | $18.6 | $21.3 | $55.9 | $70.9 |
| General and administrative expense | $7.8 | $8.0 | $23.1 | $24.5 |
| Total operating expense | $26.3 | $29.3 | $79.0 | $95.4 |
| Operating loss | $(26.3) | $(29.3) | $(79.0) | $(95.4) |
| Other income, net | $6.7 | $2.1 | $17.0 | $12.0 |
| Net loss | $(19.6) | $(27.2) | $(62.0) | $(83.4) |
| Net loss per share, basic and diluted | $(0.09) | $(0.12) | $(0.28) | $(0.39) |
| Cash used in operating activities | — | $(53.0) | $(79.9) |
- At September 30, 2023, cash and cash equivalents were $24.4 million; marketable securities were $594.9 million, with $3.0 million of interest receivable. Management reported cash, cash equivalents, and marketable securities totaling $619.3 million.
- Total assets were $630.9 million; total liabilities were $19.3 million, including $4.5 million of operating lease liabilities and a $0.6 million warrant liability. The filing reports no debt balance.
- Accumulated deficit was $329.0 million. Stockholders’ equity was $611.6 million.
Changes versus prior comparable periods
- Q3 operating expenses decreased $3.0 million year over year; nine-month operating expenses decreased $16.4 million. Management attributed most of the R&D decrease to lower third-party research and manufacturing costs, primarily following termination of the NUV-422 program, and to reduced personnel costs.
- Net loss narrowed by $7.6 million in Q3 and $21.3 million for the nine-month period. Higher investment interest income—attributed primarily to higher Treasury yields—partly offset operating losses. Nine-month warrant fair-value gains were $0.3 million in 2023 versus $9.9 million in 2022, reducing the year-over-year benefit from that noncash item.
- Operating cash use declined by $27.0 million year over year for the first nine months. Cash and cash equivalents fell $76.7 million from year-end 2022, mainly reflecting operating cash use and net purchases of marketable securities; investment purchases and sales should not be interpreted as operating burn.
Outlook, commentary, and risks
- Management expects continued operating losses and negative operating cash flows for the foreseeable future. It believes available cash, cash equivalents, and marketable securities will fund commitments for at least 12 months after the financial statements were issued; it also says additional funding may be required to complete development and support potential commercialization. No specific earnings or revenue guidance is provided.
- NUV-868 is in Phase 1 monotherapy dose escalation and Phase 1b combination dose-escalation studies; treatment was ongoing in both. The company said it expected to submit an IND for its first nominated DDC clinical candidate by year-end 2023.
- The filing describes material development uncertainty: clinical outcomes and regulatory approvals are uncertain, and the company relies on third parties for research, trials, and manufacturing. It also notes that three of the five programs pursued in February 2022 had since been discontinued or deprioritized, including the lead program; NUV-422 was discontinued after a uveitis safety signal.
- Available-for-sale securities had $3.3 million of unrealized losses at quarter-end, which management attributed primarily to interest-rate changes; it did not identify credit-related losses or expect to need to sell the securities before recovery of amortized cost.
- No significant pending legal proceedings were reported. Disclosure controls and procedures were concluded effective as of September 30, 2023, with no material quarterly change in internal control over financial reporting reported.
Important facts for investors to verify
- Whether NUV-868 trial progress and the DDC IND timeline remain on track, and whether later filings report meaningful clinical or regulatory developments.
- Whether the stated cash runway assumptions hold as R&D programs advance, and how quarterly operating cash use compares with the nine-month rate.
- How much of expense reductions reflects sustainable cost changes versus program termination, and whether development priorities or spending plans change.
- Potential dilution: 32.9 million stock options were outstanding at September 30, 2023; the filing also describes a dual-class structure that concentrates voting power with the CEO.
- Marketable-security valuation and liquidity, and the effects of interest rates on investment income and unrealized gains or losses.